News Focus
News Focus
icon url

Jagman

08/31/11 7:13 AM

#45975 RE: Realperson #45973

"Even though Aeterna Zentaris out-licensed the rights to perifosine to Keryx Biopharmaceuticals (Nasdaq: KERX ) , I still think it has potential to contribute more to the bottom line than AEZS-130, which Aeterna Zentaris owns entirely. Only about 6,000 adults are diagnosed with AGHD every year."